How Did the Indian Pharma Market Grow by 7.9% in July?
Click to start listening
Synopsis
In July, the Indian pharmaceutical market saw a remarkable 7.9% growth, driven by significant advancements in cardiac and anti-diabetes therapies. This article delves into the factors contributing to this surge, including new product launches and market dynamics that are reshaping the landscape of the Indian pharma industry.
Key Takeaways
- Indian pharmaceutical market grows by 7.9% in July.
- Cardiac and anti-diabetes therapies show strong volume growth.
- New product introductions drive market expansion.
- Biosimilars market projected to grow at 15% CAGR over five years.
- Strategic areas like biologics are reshaping the pharma landscape.
New Delhi, Aug 8 (NationPress) The Indian pharmaceutical market (IPM) experienced a growth of 7.9 percent in July this year, with the cardiac and anti-diabetes therapy sectors displaying robust volume, as reported by a recent study.
The analysis from the market research company Pharmarack indicated that the cardiac and anti-diabetes categories, which collectively make up nearly 25 percent of the overall domestic market, achieved significant value growth of 14.1 percent and 9 percent, respectively.
Various super groups, including urology and antineoplastics, each contributing around 2 percent to the IPM's monthly sales figures, also noted double-digit value growth. Additionally, the respiratory segment recorded a 9.2 percent increase in value.
“The growth observed in July for most therapies is primarily driven by new introductions and price hikes,” stated Sheetal Sapale, vice-president (commercial) at Pharmarack.
“Among the leading therapies, only cardiac and anti-infectives showcased significant volume growth. New product launches also propelled growth in the anti-diabetes category,” Sapale further explained.
The report also emphasized the ongoing positive trend in the GLP-1 agonists market, with Semaglutide and Tirzepatide leading this surge.
Semaglutide is marketed under the names Rybelsus (oral) and Wegovy (injection), while Tirzepatide is sold as Mounjaro. Both injectable treatments are designed for type 2 diabetes management and weight loss.
“There is a notable upward momentum for July, likely due to aggressive marketing of these new launch products,” Sapale noted.
Though the launch of Tirzepatide has impacted Semaglutide (Rybelsus), “we anticipate Wegovy will reinstate strong sales momentum for the molecule,” Sapale added.
The report also underscored strategic sectors that are propelling exponential growth within the Indian pharmaceutical industry, including biologics and biosimilars, which are reshaping the landscape of the Indian pharma market.
“The biosimilars market currently stands at around Rs 3,900 Crore and is projected to grow at a five-year CAGR of 15 percent,” stated Sapale.
“With the evolving patterns of diseases and associated complications, biologics and biosimilars are becoming increasingly vital in the Indian pharmaceutical sector,” Sapale concluded.
Point of View
I observe that the Indian pharmaceutical market is evolving rapidly. With advancements in therapies, particularly in cardiac and anti-diabetes segments, the industry showcases resilience and adaptability. Continuous innovation and strategic planning will be essential in maintaining this growth trajectory as we navigate a changing healthcare landscape.
NationPress
07/10/2025
Frequently Asked Questions
What was the growth percentage of the Indian pharmaceutical market in July?
The Indian pharmaceutical market grew by 7.9% in July.
What segments contributed to the market growth?
Cardiac and anti-diabetes therapy segments significantly contributed to the market growth.
Who conducted the market research?
The market research was conducted by Pharmarack.
What is the future outlook for the biosimilars market?
The biosimilars market is expected to grow at a CAGR of 15% over the next five years.
How has the introduction of new therapies impacted the market?
New therapies have driven significant growth, particularly in cardiac and anti-diabetes segments.
